Inicio › Síndromes mielodisplásicos › Carolina del Norte
Ensayos clínicos de Síndromes mielodisplásicos en Carolina del Norte
19 estudios sobre Síndromes mielodisplásicos buscan participantes en Carolina del Norte.
Ciudades en Carolina del Norte
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- y 5 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT05564390Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Duke University Medical Center, Durham
- East Carolina University, Greenville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Wake Forest University Health Sciences, Winston-Salem
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06484062Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Atrium Health Wake Forest Baptist, Winston-Salem
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health Care Institute, Winston-Salem
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT07422480Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- University of North Carolina at Chapel Hill, Chapel Hill
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- y 4 más
ReclutandoFase 1/2
Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health-Cancer Institute, Winston-Salem
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06499285ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06656494Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Duke Cancer Institute, Durham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 ago 2026 · NCT05308264Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Chapel Hill
- Research Site, Durham
ReclutandoFase 1/2
Edades de 16 en adelante · Todos los sexos · Actualizado el 20 jul 2026 · NCT07155226Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- y 4 más
ReclutandoEstudio observacional
Edades de 65 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT01137825A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Duke University, Durham
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 abr 2026 · NCT04256317The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
ReclutandoEstudio observacional
Edades de 18 a 120 · Todos los sexos · Actualizado el 13 abr 2026 · NCT01890486A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- UNC Hospital, Chapel Hill
- Duke University, Durham
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT04988555CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Duke Cancer Center, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 ene 2026 · NCT05143996SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
ReclutandoEstudio observacional
Edades de 18 a 120 · Todos los sexos · Actualizado el 27 oct 2025 · NCT01137643De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.